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Abstract Purpose: Congenital
diaphragmatic hernia (CDH) may
result in severe respiratory insufﬁ-
ciency with a high morbidity. The
role of a disturbed surfactant meta-
bolism in the pathogenesis of CDH is
unclear. We therefore studied endo-
genous surfactant metabolism in the
most severe CDH patients who
required extracorporeal membrane
oxygenation (ECMO).
Methods: Eleven neonates with
CDH who required ECMO and ten
ventilated neonates without signiﬁ-
cant lung disease received a 24-h
infusion of the stable isotope [U-
13C]
glucose. The
13C-incorporation into
palmitic acid in surfactant phospha-
tidylcholine (PC) isolated from serial
tracheal aspirates was measured.
Mean PC concentration in epithelial
lining ﬂuid (ELF) was measured
during the ﬁrst 4 days of the study.
Results: Fractional surfactant PC
synthesis was decreased in CDH-
ECMO patients compared to controls
(2.4 ± 0.33 vs. 8.0 ± 2.4%/day,
p = 0.04). The control group had a
higher maximal enrichment
(0.18 ± 0.03 vs. 0.09 ± 0.02 APE,
p = 0.04) and reached this maximal
enrichment earlier (46.7 ± 3.0 vs.
69.4 ± 6.6 h, p = 0.004) compared
to the CDH-ECMO group, which
reﬂects higher and faster precursor
incorporation in the control group.
Surfactant PC concentration in ELF
was similar in both groups.
Conclusion: These results show that
CDH patients who require ECMO
have a decreased surfactant PC syn-
thesis, which may be part of the
pathogenesis of severe pulmonary
insufﬁciency and has a negative
impact on weaning from ECMO.
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Introduction
Congenital diaphragmatic hernia (CDH) may result in
severe neonatal pulmonary insufﬁciency due to lung
hypoplasia, pulmonary hypertension and the sequelae of
ventilatory support [1]. The mortality is variable
depending on the case and center selection and the ability
to use a variety of treatment modalities [2–4].
Intensive Care Med (2009) 35:1754–1760
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CDH lamb model and the nitrofen-induced CDH rat
model, suggest decreased surfactant parameters in lung
tissue, but not on the individual cellular level [5–10]. In
vitro studies in isolated type II cells of the CDH lamb
model show decreased incorporation of precursor in sur-
factant phosphatidylcholine (PC), suggesting decreased
surfactant synthesis [8, 9].
The scarce data in humans are more controversial.
No difference in the amniotic lecithin/sphingomyelin
ratio between CDH and control fetuses was found [11],
but amniotic surfactant protein A (SP-A) was reported
to be lower in CDH fetuses who died or required
ECMO [12]. Autopsy studies in CDH infants showed
decreased SP-A levels in the lungs [13, 14]. Recently,
Boucherat et al. [15] concluded that no surfactant
deﬁciency exists in lungs of fetuses with CDH. Earlier,
we showed that the concentration of surfactant PC in
bronchoalveolar lavage from CDH patients was not
different from control patients [16]. Within this context,
Cogo et al. [17–19] studied surfactant metabolism with
the use of stable isotopes in infants with CDH on
mechanical ventilation, but not on ECMO, and com-
pared them with ventilated control infants. In CDH
infants without ECMO they found decreased amounts of
PC and SP-A in the tracheal aspirates, a decreased
surfactant disaturated PC (DSPC) pool size and a higher
DSPC turnover rate, but no decreased synthesis of sur-
factant DSPC. In an earlier study, we did not ﬁnd a
change in surfactant PC pool size or in turnover rate in
high-risk CDH patients who required ECMO when
compared to infants with meconium aspiration on
ECMO or to ventilated infants without ECMO [20].
Although different studies from the CDH study group
did not reveal a beneﬁt of routine use of exogenous sur-
factant, abnormalities in surfactant metabolism kinetics or
secondary inactivation of surfactant due to the method of
artiﬁcial ventilation cannot be excluded [21, 22]. We
hypothesized that surfactant synthesis in CDH patients
who require ECMO is decreased compared to control
infants. Therefore, we studied the surfactant PC kinetics
in vivo in CDH patients who required ECMO with the use
of infused stable isotope tracers.
Patients and methods
Patients
The study was performed in the intensive care units of the
Erasmus MC-Sophia in a 1.5-year period. We studied two
groups of neonates (Table 1): neonates with left-sided
CDH who required veno-arterial ECMO (CDH-ECMO)
(n = 11) and a group of ventilated term neonates without
signiﬁcant lung disease (control) (n = 10). The diagnoses
of the ten ventilated control patients were varied
(gastroschisis, cerebral infarction, small to moderate
omphalocele (n = 2), anal atresia, thymic cyst, spina bi-
ﬁda, pentalogy of Cantrell and hypoxic ischemic
encephalopathy (n = 2) without primary pulmonary
anomaly or signs of abnormal lung development at the
time of the study. The study was approved by the local
medical ethics committee, and all patients were studied
after receiving written informed consent from the parents.
Our institution uses a standardized protocol for treat-
ment of CDH patients, consisting of: planned vaginal
delivery in prenatal diagnosed cases, immediate endo-
tracheal intubation at birth, followed by high frequency
oscillation (Sensormedics) as the primary ventilator
mode. We used low settings: frequency 8–10 Hz,
MAP 12–14 mmHg, DP 30–40 mmHg and FiO2 to
maintain preductal saturations C95%, PCO2 between 7.0
and 7.5 kPa, allowing permissive hypercapnia. Insertion
of a double-lumen nasogastric tube with the application of
continuous suctioning for decompression of the stomach,
cardiac ultrasound to evaluate right–left shunting and
structural defects, ﬂuid restriction (40–60 ml/kg body
weight on day 1), no muscle paralysis, sedation with
midazolam [0.1 mg/(kg h)] and morphine [5–15 mcg/
(kg h)], and support of systemic blood pressure by
dopamine and eventually norepinephrine [23].
The entry criteria for ECMO were: gestational age of
C34 weeks, birth weight of C2,000 g, mechanical venti-
lation for\7 days, AaDO2 of[600 torr ([80 kPa) for 8 h
and OI [25 for 4 h. A minimal preductal PaO2 of
C75 torr (C10 kPa) was an additional entry criterion for
CDH patients to at least ensure a reasonable chance of
weaning from ECMO later. During ECMO, ventilator
settings were routinely reduced to a peak inspiratory
pressure of 9–12 mmHg (12–16 cm H2O), positive end-
expiratory pressure of *4 mmHg (5–6 cm H2O), respi-
ratory rate of 10–15 breaths/min, and FiO2 of 0.25–0.3
using conventional ventilation (Babylog, Drager).
Table 1 Patient characteristics
CDH-ECMO Control
n = 11 n = 10
Gestational age (week) 38.2 ± 0.8 39.0 ± 0.4
Birth weight (g) 3,077 ± 150 3,189 ± 237
Apgar at 5 min 6.4 ± 0.8 7.0 ± 1.5
Male/female 7/4 5/5
Pneumothorax (n)
a 51
Duration of ventilation (days) 28.3 ± 5.1 25.6 ± 9.9
Age at start study (h) 42.9 ± 4.5 137.6 ± 45.5
b
Survivors (n)5 8
a In all cases occurring before the start of ECMO, sometimes even
directly after birth
b Signiﬁcantly different (p = 0.03)
1755Isotope infusion and sample collection
All included patients received a 24-h continuous intrave-
nous infusion of [U-
13C] glucose [0.17 mg/(kg min)],
Campro Scientiﬁc, Veenendaal, The Netherlands, and
Cambridge Isotope Laboratories, Inc., Andover, MA). The
start of the isotope infusion was deﬁned as the start of the
study (t = 0). Before and during the label infusion, 1 ml
of blood was drawn every 6 h for determination of
13C-
enrichment of plasma glucose. Samples were collected in
an EDTA tube, immediately placed on ice and centrifuged
at 2,500 rpm for 10 min. The plasma was stored at -70C
until it was analyzed. Tracheal aspirates were obtained
every 4–6 h during the time the infant was intubated, with
a maximum of 2 weeks. The tracheal suctioning was
performed during routine patient care and did not deviate
from the normal clinical care, which consisted of tracheal
suctioning every nursing shift, or more frequently if it
seemed clinically necessary. Tracheal aspirates were
immediately placed at -20C, until further processing.
Analytical procedure
The plasma and tracheal aspirates were processed as
described before [19, 24]. Brieﬂy, plasma was delipidat-
ed, and glucose was isolated and derivatized to an
aldonitril pentacetate derivative [25]. Organic extraction
was used to isolate surfactant lipids in the tracheal aspi-
rates [26], and surfactant PC was recovered by thin layer
chromatography [27]. Isotopic enrichments were mea-
sured by mass spectrometry, as described before [24]. The
13C-enrichments were expressed as atom percent excess
(APE), which represents the increase in the percentage of
13C atoms in total carbon dioxide from the combusted
compounds above baseline enrichment (before infusion).
Enrichments were corrected for the contribution of unla-
beled carbon atoms added during derivatization.
Determination of composition and concentration
Fatty acid composition of surfactant PC and the amount
of surfactant PC were determined by gas-chromatography
(Hewlett-Packard, 5890 series II, Amstelveen, The
Netherlands) [16]. The concentration of surfactant PC in
the epithelial lining ﬂuid (ELF) was calculated by cor-
recting for dilution of the ELF during endotracheal
suction: dilution factor = [urea]serum/[urea]supernatant [28].
Calculations
Calculations were performed as described before [24].
Time of ﬁrst appearance (Tapp) is deﬁned as the time delay
between the start of the isotope infusion and the ﬁrst
appearance of the label in surfactant PC. Time of maxi-
mal enrichment (Tmax) is the time where maximum
enrichment is reached (Emax). Half-life of surfactant PC
(T) was calculated from the downslope of the enrich-
ment versus time curve. Fractional synthesis time (FSR)
of palmitic acid in surfactant PC represents the percentage
of the total PC-palmitate pool synthesized de novo from
plasma glucose per day.
Data analyses
Data are presented as mean ± standard error of the mean
(SEM). The non-parametric Mann-Whitney U test was
applied to compare groups. Spearman correlation was
used to evaluate correlations between surfactant kinetic
parameters, surfactant PC concentration and patient
characteristics. Signiﬁcance was accepted at a value of
p\0.05 (two-sided).
Results
Seven CDH-ECMO patients were diagnosed prenatally
and were born in our hospital; four were postnatal refer-
rals. ECMO was started at 15.1 ± 2.7 h after birth and
had a duration of 226 ± 34 h. The time on ECMO before
the start of the study was 27.8 ± 4.2 h. No baby received
treatment with exogenous surfactant. All patients were
successfully decannulated. The non-survivors in the
CDH-ECMO group died at 28.2 ± 5.5 days of life
because of therapy-resistant pulmonary hypertension.
Unfortunately, lung body weight ratios are not available
as no non-survivor autopsies were authorized. Two
patients with hypoxic ischemic encephalopathy in the
control group died because of severe cerebral damage on
day 6, respectively, day 15 of life. Clinical characteristics
are described in Table 1.
Ventilatory parameters
Nine CDH patients were ventilated with high frequency
oscillation (HFO) before ECMO; two CDH patients were
conventionally ventilated. Ventilation and oxygenation
characteristics of the CDH patients before the start of
ECMO were as follows: mean airway pressure (MAP) was
13.5 ± 1.4 mmHg (18.3 ± 1.9 cm H2O), oxygenation
index [OI = (MAP 9 FiO2)/PaO2I] was 40.6 ± 8.1, and
the alveolar-arterial oxygen gradient (AaDO2 = PaO2 -
[(713 9 FiO2) - (PaCO2/0.8)]) was 593.0 ± 10.2 torr
(79 kPa). The ten control patients were conventionally
ventilated for 26 ± 10 days following surgery or because
of apneic attacks. These patients had mild ventilatory
settings: FiO2: 0.26 ± 0.03, MAP: 5.9 ± 0.6 mmHg
1756(8.0 ± 0.8 cm H2O), ventilatory rate: 31 ± 4/min, posi-
tive inspiratory pressure (PIP): 14.1 ± 1.3 mmHg
(19.2 ± 1.8 cm H2O) and positive end-expiratory pres-
sure (PEEP): 3.2 ± 0.1 mmHg (4.4 ± 0.2 cm H2O).
Surfactant kinetic parameters (Table 2)
The
13C-enrichment of plasma glucose was in steady
state (Egluc) in all infants between t = 6 and 24 h, and
was similar in both groups (Table 2). Despite a larger
blood volume in ECMO patients due to the extracor-
poreal circuit, this was expected as the plateau
13C
enrichment of glucose during a continuous infusion is
determined by the rate of appearance of glucose in the
plasma and not by the volume of distribution. Figure 1
shows the
13C-glucose incorporation of surfactant PC
palmitate in sequential tracheal aspirates in the CDH-
ECMO patients and control patients. The incorporation
of
13C from the precursor glucose into surfactant PC
palmitate started somewhat later (Tapp) in the CDH-
ECMO patients, but the difference with controls was not
signiﬁcant. The CDH-ECMO group had a signiﬁcantly
lower maximal enrichment (Emax), which also was
reached later (Tmax) compared to the control group.
These indices reﬂect reduced precursor incorporation
into surfactant PC in the CDH-ECMO group (Table 2).
FSR was more than three times lower in CDH-ECMO
patients than in control patients, but the half-life of
label disappearance from surfactant PC was not differ-
ent between groups (Table 2). No correlation between
surfactant kinetic parameters and patient characteristics
were found, except for a negative correlation between
surfactant half-life and gestational age in the CDH-
ECMO group (p = 0.03).
The surfactant PC concentration in ELF during the
ﬁrst 4 days of the study was equal in both groups
(Table 2). No correlations were found between the sur-
factant PC concentration and the clinical or surfactant PC
kinetic parameters.
Surfactant PC concentration in ELF during the ﬁrst
4 days of the study was not different between the survi-
vors and non-survivors of the CDH-ECMO group
(9.5 ± 3.6 vs. 4.5 ± 1.8 mg/ml ELF, p = 0.27). There
were also no differences in surfactant kinetic parameters
between the survivors and non-survivors of the CDH-
ECMO group. Non-survivors had a lower gestational age
than survivors of the CDH-ECMO group (37.1 ± 0.6 vs.
39.6 ± 0.5 weeks, p = 0.02).
In the current study, we also measured fractional
surfactant PC synthesis in two CDH patients who did not
require ECMO. The kinetic parameters of these two CDH
patients not requiring ECMO were: Tapp 13 and 26 h,
Table 2 Surfactant kinetic parameters
CDH-ECMO n = 11 Control n = 10 p Value
FSR (%/day) 2.4 ± 0.3 8.0 ± 2.4 0.04
Tapp (h) 18.0 ± 2.6 11.7 ± 1.1 0.11
Tmax (h) 69.8 ± 6.6 46.7 ± 3.0 0.004
Emax (APE) 0.09 ± 0.02 0.18 ± 0.03 0.04
Half life (h) 69.0 ± 10.3 63.4 ± 10.7 0.79
Egluc (APE) 2.0 ± 0.1 2.2 ± 0.3 0.75
PC (mg/ml ELF) 6.6 ± 1.9 12.8 ± 2.6 0.78
Phosphatidylcholine (PC) concentration in epithelial lining ﬂuid
(ELF) during the ﬁrst 4 days of the study. Data are expressed as
mean ± standard error of mean (SEM)
FSR Fractional surfactant synthesis, Tapp time of ﬁrst appearance of
the label, Tmax time of maximal enrichment, Emax maximal
enrichment expressed as atom percent excess (APE), Egluc mean
enrichment of plasma glucose in steady state
The non-parametric Mann–Whitney U test was applied to compare
groups
12-24 36-48 60-72 96-120 144-168 192-216 240-260 
0,000
0,020
0,040
0,060
0,080
0,100
0,120
0,140
0,160
0,180
0,200
time intervals
A
P
E
CDH-ECMO
controls
Fig. 1
13C-enrichment of
palmitic acid in surfactant
phosphatidylcholine in
sequential tracheal aspirates.
Neonates with congenital
diaphragmatic hernia on
extracorporeal membrane
oxygenation (CDH-ECMO)
(closed circles) and control
patients (open circles) received
a 24-h [U-
13C] glucose infusion
as precursor for
phosphatidylcholine-palmitate
in surfactant. Data are
expressed as mean and standard
error of the mean (SEM) of time
intervals of 12 and 24 h (with
the 24 h interval starting at
72 h)
1757Tmax 39 and 43 h, Emax 0.17 and 0.23 APE, FSR 7 and
14%/day, PC concentration in ELF 3.7 and 7.6 mg/ml,
half-life 56.8 h in one patient only.
Seven CDH-ECMO patients and two control patients
of the current study had also received an endotracheal
tracer to calculate the total lung surfactant pool size [20].
By multiplying the FSR by the pool size in these patients,
we were able to calculate the ‘net absolute synthesis rate.’
The mean net synthesis rate of seven CDH-ECMO
patients was 2.7 ± 0.8 mg/(kg d), which is comparable
with that of premature infants [2.7 ± 0.8 mg/(kg d)] [29].
In the two control patients the net synthesis rate was much
higher at 11.2 and 11.5 mg/(kg d).
Discussion
We report a signiﬁcantly reduced surfactant PC synthesis
in infants with CDH who require ECMO compared to
ventilated control infants. The surfactant PC synthesis
was studied in vivo with the use of stable isotopes by
measuring incorporation rates of precursor glucose into
surfactant PC (FSR 2.4 ± 0.33 vs. 8.0 ± 2.4%/day,
p = 0.04). These results are in line with studies in animal
models that also found decreased PC synthesis in isolated
type II cells or lungs from CDH fetuses of the rat and
lamb model [8, 9, 30].
In an earlier report in CDH infants who did not require
ECMO, we found no decreased fractional synthesis rates
of surfactant DSPC in comparison to ventilated control
infants [18, 19]. A plausible explanation for the difference
in surfactant synthesis is that the CDH infants who require
ECMO have more severe pulmonary hypoplasia and/or
immaturity than CDH patients who do not require ECMO.
Indeed, pulmonary insufﬁciency in the CDH infants who
did not require ECMO in our two previous studies was
clearly less severe with a lower OI (7.8–10 vs. 40.6), other
ventilator parameters and a lower mortality. In agreement
with our previous studies, the kinetic parameters of the
two CDH patients not requiring ECMO were very similar
to these in the ventilated control group.
The decrease in surfactant synthesis in this study on
CDH-ECMO patients is felt to be secondary to progressing
injury to the lungs. Bohlin et al. [31] measured surfactant
synthesis in term infants using
13C-acetate as precursor.
They found a decreased FSR in term infants with severe
respiratory failure, similar to the FSR of preterm infants
with respiratory distress syndrome, suggesting that a lower
FSR might be reﬂective of severely injured and dysfunc-
tional lungs. The FSR we found in our CDH patients is
also similar to the FSR in preterm infants with RDS
(*2.7%/day) after
13C-glucose infusion as precursor [24].
Our results of a lower FSR in CDH-ECMO cannot be
simply explained by the smaller size of the lungs. Firstly,
if pool size were just decreased in relation to smaller
lungs, FSR would not be inﬂuenced when synthesis per
lung unit would remain the same. Secondly, we did not
ﬁnd a decreased PC pool size in our previous study on
CDH-ECMO patients in comparison to infants with
meconium aspiration on ECMO or to non-ECMO patients
[20]. Thirdly, no difference in net absolute synthesis
between CDH infants without ECMO and ventilated
controls was found by the use of dual tracers [18]. The net
absolute synthesis rate calculated in seven CDH-ECMO
patients is comparable with that of premature infants
[2.7 ± 0.8 mg/(kg d)] [29]. In the two control patients the
net synthesis rate was much higher.
An alternative explanation for the decreased surfactant
synthesis in CDH-ECMO patients is the severe pulmonary
hypertension leading to ECMO requirement. It could be
speculated that reduced blood ﬂow through the lungs due
to severe pulmonary hypertension provides less substrate
forsurfactant synthesis.In addition,duringVA-ECMOthe
lung blood ﬂow is also signiﬁcantly lower since the circuit
blood ﬂow drained from the right atrium is shunting the
lungs and directly diverted to the ascending aorta. Earlier
we found an increased surfactant synthesis in premature
infants who had a clinically relevant persistent ductus
arteriosus, a situation that leads to an increased lung blood
ﬂow [29]. Furthermore, ECMO is known to result in
increased vascular permeability and cytokine release,
which could inﬂuence surfactant kinetics [32].
From animal studies it is known that physical stretch of
the alveoli stimulates surfactant synthesis and secretion
[33]. Physical stretch during ECMO treatment is reduced
because low ventilatory settings (PIP 9–12 mmHg) are
used as part of the concept of ‘‘lung rest’’ and could pos-
sibly decrease surfactant synthesis. However, we found no
difference in surfactant synthesis in preterm infants
ventilated with high frequency oscillation compared to
conventional ventilation, which argues against the inﬂu-
ence of stretch in vivo on surfactant synthesis [34].
In the current study we did not ﬁnd a signiﬁcant dif-
ference in the concentration of PC in ELF during the ﬁrst
4 days between the CDH patients on ECMO and controls
(Table 2). The PC concentration in ELF of the CDH-
ECMO patients in this study (6.6 mg/ml) is comparable
with other data of CDH patients on ECMO (*6.5 mg/ml)
and with the results of CDH patients not requiring ECMO
(*4 mg/ml) [16, 19, 20]. In preterm infants, using the
same method, a lower surfactant PC concentration was
found (2.4 mg/ml) [35]. Earlier, we showed that surfac-
tant PC pool size in CDH patients requiring ECMO was
not decreased when compared with the pool sizes of
neonates with meconium aspiration syndrome requiring
ECMO and neonates who did not require ECMO [20].
However, Cogo et al. found lower concentrations of
DSPC in ELF and SP-A in tracheal aspirates of CDH
patients who were not on ECMO compared to controls.
Surfactant PC concentration in ELF during the study
was not signiﬁcantly lower in the non-survivors of our
1758CDH-ECMO group, though in the literature a correlation
between surfactant composition and survival have been
mentioned [12, 36].
In conclusion, the surfactant PC synthesis in neonates
with CDH on ECMO is decreased compared to ventilated
control patients. Our study does not completely solve the
problem of which mechanism is responsible for this
decreased synthesis. In fact, it would have been better if
we also included another CDH no ECMO group to
compare, which would be more convincing to show the
relation of the severity of the CDH on the surfactant
metabolism. As in previous studies, we did not ﬁnd a
decreased DSPC synthesis in milder CDH patients who
did not require ECMO, and we therefore speculate that
the decreased PC synthesis in CDH-ECMO patients is
related to the severity of the pulmonary insufﬁciency,
either caused by immaturity or by ventilator-induced
injury, and/or by the low pulmonary blood ﬂow during
severe pulmonary hypertension and especially during
ECMO. This is also supported by the study of Boucherat
et al. [15] who found no deﬁcient surfactant storage in
human fetuses with CDH. From the present study it has
become clear that CDH patients who require ECMO are
quite a different group of patients than those with CDH
without ECMO. The ECMO patients have a structural and
functional pulmonary immaturity that sets them apart
[37].
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